UCB (OTCMKTS:UCBJF) Sees Unusually-High Trading Volume – Time to Buy?

UCB SA (OTCMKTS:UCBJF) shares saw unusually-high trading volume on Tuesday . Approximately 9,277 shares changed hands during mid-day trading, an increase of 1,063% from the previous session’s volume of 798 shares.The stock last traded at $263.3625 and had previously closed at $263.84.

Analyst Ratings Changes

Several research analysts have recently weighed in on UCBJF shares. Piper Sandler restated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a research note on Monday. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, UCB currently has a consensus rating of “Moderate Buy”.

UCB Trading Down 2.0%

The business has a fifty day moving average of $292.21 and a two-hundred day moving average of $299.76. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.